The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prognostic and predictive tumor-based biomarkers in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (IFN) with or without bevacizumab (Bev): Results from CALGB (Alliance) 90206.
Harriet M. Kluger
No relevant relationships to disclose
Susan Halabi
No relevant relationships to disclose
Nicole C Solomon
No relevant relationships to disclose
Lucia Jilaveanu
No relevant relationships to disclose
Christopher Zito
No relevant relationships to disclose
Joshua Sznol
No relevant relationships to disclose
Andrew B. Nixon
No relevant relationships to disclose
Brian I. Rini
Research Funding - Roche/Genentech
Eric Jay Small
No relevant relationships to disclose
Daniel J. George
Research Funding - Genentech